Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Tenax Therapeutics is expected to report Q1 2026 results before the market opens on May 13, with analysts forecasting ($0.40) EPS and an earnings call set for May 15 at 4:00 PM ET.
• Analyst sentiment is bullish—several firms raised ratings and price targets into the mid‑$30s, leaving a consensus rating of “Moderate Buy” and an average price target of $29.67.
• The stock trades around $12.49 with a market cap near $215M; Tenax posted a prior quarter EPS of ($0.38) that beat expectations, but analysts still forecast about -$3 EPS for the current and next fiscal years.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last issued its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $0.88. On average, analysts expect Tenax Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Tenax Therapeutics Price Performance

Shares of NASDAQ:TENX opened at $12.49 on Wednesday. The company's fifty day moving average price is $13.80 and its 200-day moving average price is $11.91. The firm has a market capitalization of $214.83 million, a price-to-earnings ratio of -9.39 and a beta of 1.00. Tenax Therapeutics has a one year low of $5.34 and a one year high of $18.38.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on TENX shares. Guggenheim increased their price target on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a report on Monday, March 16th. Cantor Fitzgerald started coverage on shares of Tenax Therapeutics in a report on Tuesday, March 17th. They issued an "overweight" rating and a $35.00 price target on the stock. Lifesci Capital raised shares of Tenax Therapeutics to a "strong-buy" rating in a report on Thursday, March 12th. Finally, William Blair reissued an "outperform" rating on shares of Tenax Therapeutics in a report on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $29.67.

Institutional Investors Weigh In On Tenax Therapeutics

Several institutional investors have recently added to or reduced their stakes in TENX. Virtu Financial LLC purchased a new stake in Tenax Therapeutics during the 3rd quarter valued at $92,000. Citadel Advisors LLC boosted its position in Tenax Therapeutics by 318.1% during the 3rd quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company's stock valued at $329,000 after buying an additional 32,908 shares during the period. Millennium Management LLC boosted its position in Tenax Therapeutics by 34.2% during the 3rd quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company's stock valued at $2,387,000 after buying an additional 79,998 shares during the period. Woodline Partners LP purchased a new stake in Tenax Therapeutics during the 3rd quarter valued at $671,000. Finally, Geode Capital Management LLC boosted its position in Tenax Therapeutics by 61.8% during the 4th quarter. Geode Capital Management LLC now owns 55,699 shares of the specialty pharmaceutical company's stock valued at $679,000 after buying an additional 21,274 shares during the period. Hedge funds and other institutional investors own 1.67% of the company's stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company's proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax's lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.